{"id":1007359,"date":"2026-10-01T07:40:20","date_gmt":"2026-10-01T11:40:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/"},"modified":"2026-10-01T07:40:20","modified_gmt":"2026-10-01T11:40:20","slug":"iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/","title":{"rendered":"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Leader in Global Drug Development of T Cell Therapies<\/em>\n      <\/p>\n<p>PHILADELPHIA, Oct.  01, 2026  (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.<\/p>\n<p>\u201cWe are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,\u201d said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. \u201cNoah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track record will be instrumental as we work to bring TIL therapy to many more patients in new markets, earlier treatment settings, and additional solid tumor cancers.\u201d<\/p>\n<p>As Chief Medical Officer of Arvinas Pharmaceuticals, Dr. Berkowitz led the clinical strategy that resulted in the first-ever U.S. Food and Drug Administration (FDA) approval of a targeted protein degradation therapy and expanded the company\u2019s clinical programs across cancer, neurological, and rare diseases. Previously, Dr. Berkowitz served as Senior Vice President and Therapeutic Area Head, Hematology at Bristol Myers Squibb, where he oversaw the full scope of drug development for the company\u2019s benign and malignant hematology programs and, on an interim basis, its cell therapy programs. His global development teams achieved regulatory approvals for the chimeric antigen receptor (CAR) T cell therapies Abecma and Breyanzi, two of the first cell therapies approved for multiple myeloma and large B cell lymphoma, respectively. Clinical programs under his leadership helped drive recent annual sales of Reblozyl above $2 billion. Earlier, Dr. Berkowitz held leadership positions of increasing responsibility in clinical development across multiple cancer indications at Novartis. Dr. Berkowitz completed a clinical investigation fellowship in medical oncology at the National Cancer Institute (NCI). He holds an M.D. and Ph.D. in molecular immunology from Columbia University.<\/p>\n<p>\u201cI am excited to join Iovance at this critical inflection point to explore broader applications for TIL technology in new indications and treatment settings,\u201d stated Dr. Berkowitz. \u201cThe Iovance TIL platform demonstrates remarkable clinical results and represents the new frontier across solid tumors, including next-generation approaches. I look forward to contributing to the Iovance vision to expand the reach of this transformative treatment to patients who need it most.\u201d<\/p>\n<p>In connection with Dr. Berkowitz\u2019s appointment, Iovance approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 450,000 shares of Iovance\u2019s common stock to Dr. Berkowitz. The awards were granted on September 30, 2026 (the date of grant), under Iovance\u2019s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company\u2019s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted has an exercise price of $14.82, the closing price of Iovance\u2019s common stock on the date of grant. Each stock option and each restricted stock unit vests over a three-year period, with one-third of the shares vesting on the first anniversary of Dr. Berkowitz\u2019s start date (the first vesting date) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the first vesting date. In addition, certain of these restricted stock units may vest upon the achievement of performance milestones based on specified regulatory results rather than time-based vesting. The foregoing vesting is subject to continued employment with Iovance through the applicable vesting dates.<\/p>\n<p>\n        <strong>About Iovance Biotherapeutics, Inc.<\/strong>\n      <\/p>\n<p>Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi\u00ae (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The\u00a0<a href=\"https:\/\/www.iovance.com\/our-science\/til-platform\/\" rel=\"nofollow\" target=\"_blank\">Iovance TIL platform<\/a>\u00a0spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>Amtagvi\u00ae and its accompanying design marks, Proleukin<sup>\u00ae<\/sup>, Iovance<sup>\u00ae<\/sup>, and IovanceCares\u2122\u00a0are trademarks and registered trademarks of\u00a0Iovance Biotherapeutics, Inc.\u00a0or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.<\/p>\n<p>Information on Iovance\u2019s broad, industry-leading patent portfolio is available on the Intellectual Property page on\u00a0<a href=\"http:\/\/www.iovance.com\/\" rel=\"nofollow\" target=\"_blank\">www.iovance.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>Certain matters discussed in this press release are \u201cforward-looking statements\u201d of Iovance Biotherapeutics, Inc. (hereinafter referred to as the \u201cCompany,\u201d \u201cwe,\u201d \u201cus,\u201d or \u201cour\u201d) within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Without limiting the foregoing, we may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cachievable,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cforecast,\u201d \u201cguidance,\u201d \u201coutlook,\u201d \u201cmay,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled \u201cRisk Factors\u201d in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>IR@iovance.com<br \/>650-260-7120 ext. 150<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>PR@iovance.com<br \/>650-260-7120 ext. 150<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGJkMzc0OTMtNDE5NC00YzVjLWI0NGQtOWM2ZjFmNjVmMjk5LTEwMzA3NjktMjAyNi0xMC0wMS1lbg==\/tiny\/Iovance-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. \u201cWe are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,\u201d said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. \u201cNoah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007359","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. \u201cWe are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,\u201d said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. \u201cNoah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track &hellip; Continue reading &quot;Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-01T11:40:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer\",\"datePublished\":\"2026-10-01T11:40:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/\"},\"wordCount\":1112,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/\",\"name\":\"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=\",\"datePublished\":\"2026-10-01T11:40:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk","og_description":"Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) &#8212; Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. \u201cWe are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,\u201d said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. \u201cNoah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track &hellip; Continue reading \"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-01T11:40:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer","datePublished":"2026-10-01T11:40:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/"},"wordCount":1112,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/","name":"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=","datePublished":"2026-10-01T11:40:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNzU5MSM3ODczNjE0IzIwMTkxOTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007359"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}